Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.

@article{Peer2004FluoxetineIM,
  title={Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.},
  author={Dan Peer and Yaron Dekel and Dina Melikhov and Rimona Margalit},
  journal={Cancer research},
  year={2004},
  volume={64 20},
  pages={7562-9}
}
Multidrug resistance (MDR) operated by extrusion pumps such as P-glycoprotein and multidrug-resistance-associated-proteins, is a major reason for poor responses and failures in cancer chemotherapy. MDR modulators (chemosensitizers) were found among drugs approved for noncancer indications and their derivatives. Yet toxicity, adverse effects, and poor solubility at doses required for MDR reversal prevent their clinical application. Among newly designed chemosensitizers, some still suffer from… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.

Journal of controlled release : official journal of the Controlled Release Society • 2015
View 3 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2003
View 10 Excerpts
Highly Influenced

MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2002
View 4 Excerpts
Highly Influenced

Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56 lymphocytes after oral and intravenous administration

J Stewart A. Steiner, G Mellows, B Laguda, D Norris, P. Bevan
Clin Cancer Res • 2000
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…